Global Personalized Cell Therapy Market Is Estimated
To Witness High Growth Owing To Rising Prevalence of Chronic Diseases and
Increasing Investments in Research and Development.

The Global Personalized Cell Therapy
Market is estimated to be valued at US$
8,046.3 Million In 2018 and is expected to exhibit a CAGR of 23.5% over the forecast period 2019-2027, as highlighted in
a new report published by Coherent Market Insights.



Market Overview:

Personalized cell therapy involves the use of patient-specific cells to treat
various diseases and conditions. This approach offers targeted and customized
treatment options, resulting in better patient outcomes. The market for
personalized cell therapy is driven by the rising prevalence of chronic
diseases, such as cancer and autoimmune disorders, which require advanced
treatment options. The increasing investments in research and development
activities to explore the potential of cell-based therapies are also
contributing to the market growth. Moreover, the technological advancements in
cell therapy manufacturing and the growing demand for regenerative medicine are
further driving market expansion.



Market Dynamics:

The Personalized Cell Therapy Market dynamics driving the growth of the personalized cell
therapy market can be attributed to two key factors: the rising prevalence of
chronic diseases and increasing investments in research and development.



1. Rising prevalence of chronic diseases: The increasing burden of chronic diseases,
such as cancer, cardiovascular diseases, and autoimmune disorders, is driving
the demand for personalized cell therapies. These therapies offer potential
solutions for patients who do not respond to traditional treatments or are
unresponsive to conventional medicines. The personalized approach of cell
therapy provides targeted treatment options, resulting in improved patient
outcomes and reduced side effects.



2. Increasing investments in research and development: There has been a
significant increase in investments in research and development activities
related to personalized cell therapy. This is primarily driven by the growing
recognition of the potential of cell-based therapies in addressing unmet
medical needs and the demand for innovative treatment options. The advancements



SWOT Analysis:



Strength: The personalized cell therapy market has significant strength in its
potential to revolutionize medical treatment by delivering personalized and
targeted therapies for various diseases. This approach shows promise for
improved patient outcomes and reduced medical costs.



Weakness: One weakness of personalized cell therapy is its high cost, which may
limit access for certain patient populations. Additionally, the complexity of
the manufacturing and regulatory processes for personalized cell therapy
products presents a challenge for widespread adoption and scalability.



Opportunity: The personalized cell therapy market has the opportunity to expand
its applications beyond existing indications such as cancer and autoimmune
diseases. There is a growing interest in using cell therapy approaches for
neurodegenerative disorders and cardiovascular diseases, which could create new
market segments and revenue streams.



Threats: One threat to the personalized cell therapy market is the potential
for adverse events during treatment, including immune reactions and
complications related to the administration of genetically modified cells.
Regulatory challenges and the need for significant investment in research and
development also pose threats to market growth.



Key Takeaways:



The global personalized cell therapy market is expected to witness high growth,
exhibiting a compound annual growth rate (CAGR)
of 23.5% over the forecast period of 2019-2027. This growth can be
attributed to increasing demand for personalized and targeted therapies,
advancements in cell manufacturing technologies, and a favorable regulatory
environment.



In terms of regional analysis, North America is projected to be the fastest
growing and dominating region in the personalized cell therapy market. Factors
driving this growth include a strong presence of key players in the region, a
well-established healthcare infrastructure, and increasing investments in cell
therapy research and development.



Key players operating in the personalized cell therapy market include Cytori
Therapeutics Inc., Bellicum Pharmaceuticals, Inc., Saneron CCEL Therapeutics,
Inc., MolMed S.p.A., Vericel Corporation, Novartis AG, Gilead Sciences, Inc.,
Celgene Corporation, Bluebird Bio, Inc., and Aurora Biopharma Inc. These
companies are actively involved in research and development, strategic
collaborations, and mergers and acquisitions to gain a competitive edge in the
market.